VRDN Q1 2021 Earnings — Viridian Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

VRDNViridian Therapeutics, Inc.

$3B

Q1 2021 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$1M+75.2% YoY

Gross Profit

-$12M-851.5% margin

Operating Income

-$19M-1276.0% margin

Net Income

-$18M-1272.2% margin

EPS (Diluted)

$-2.91

QoQ Revenue Growth

+2587.0%

Cash Flow

Operating Cash Flow

-$12M

Free Cash Flow

-$12M

Stock-Based Comp.

$3M

Balance Sheet

Total Assets

$123M

Total Liabilities

$17M

Stockholders' Equity

$106M

Cash & Equivalents

$46M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$1M	$828,000	+75.2%
Gross Profit	-$12M	$828,000	-1592.1%
Operating Income	-$19M	-$8M	-131.5%
Net Income	-$18M	-$8M	-129.5%

Revenue Segments

Collaboration Revenue, Related Party

$1M100%